

## Publikationen Priv. – Doz. Dr. Simon Schneider

### Originalartikel

1. Influence of radiotherapy on cardiac implantable devices and leads—a single-institution analysis and critical evaluation of current guidelines.  
Warmbrunn J, Straube C, Haase HU, Sinnecker D, Laugwitz KL, Combs SE, **Schneider S**, Habermehl D. *Strahlenther Onkol.* 2025 Jan 10
2. Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial.  
Rheude T, Ruge H, Altaner N, Pellegrini C, Alvarez Covarrubias H, Mayr NP, Cassese S, Kufner S, Taniguchi Y, Thilo C, Klos M, Erlebach M, **Schneider S**, Jurisic M, Laugwitz KL, Lange R, Schunkert H, Kastrati A, Krane M, Xhepa E, Joner M. *Eur Heart J.* 2024
3. Byrne RA, Alfonso F, **Schneider S**, Maeng M, Wiebe J, Kretov E, Bradaric C, Rai H, Cuesta J, Rivero F, Hoppmann P, Schlichtenmaier J, Christiansen EH, Cassese S, Joner M, Schunkert H, Laugwitz KL and Kastrati A. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. *European heart journal.* 2019;40:167-176.
4. **Schneider S**, Olliges E, Schmidt G, Sinnecker D, Müller A, Burgdorf C, Braun S, Holdenrieder S, Ebell H, Ladwig KH, Meissner K, Ronel J. Placebo and Nocebo Effects in Patients With Takotsubo Cardiomyopathy and Heart-Healthy Controls. *Front Psychiatry.* 2019;10:549.
5. **Schneider S**, Harada Y, Colleran R, Rai H, Bohner J, Kuna C, Kufner S, Giacoppo D, Schüpke S, Joner M, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA. Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated? *Rev Esp Cardiol (Engl Ed).* 2020;73(3):225-231.
6. Wiebe J, Hoppmann P, Colleran R, Kufner S, Valeskini M, Cassese S, **Schneider S**, Joner M, Schunkert H, Laugwitz KL, Kastrati A and Byrne RA. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. *JACC Cardiovascular interventions.* 2017;10:1222-1229.
7. Kufner S, Joner M, **Schneider S**, Tolg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA and Investigators I-D. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. *JACC Cardiovascular interventions.* 2017;10:1332-1340.
8. Echtler K, Konrad I, Lorenz M, **Schneider S**, Hofmaier S, Plenagl F, Stark K, Czermak T, Tirniceriu A, Eichhorn M, Walch A, Enders G, Massberg S and Schulz C. Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. *PLoS One.* 2017;12:e0172788.
9. Colleran R, Kufner S, Harada Y, Giacoppo D, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, **Schneider S**, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary S, Angiographic Results: Test Efficacy of S and Probucol-Eluting Versus Zotarolimus-Eluting Stents I. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. *Catheter Cardiovasc Interv.* 2017;89:367-374.

10. Buiatti A, von Olshausen G, Barthel P, **Schneider S**, Luik A, Kaess B, Laugwitz KL and Hoppmann P. Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies. *Europace*. 2017;19:378-384.
11. Wiebe J, Hoppmann P, Kufner S, Harada Y, Colleran R, Michel J, Giacoppo D, **Schneider S**, Cassese S, Ibrahim T, Schunkert H, Laugwitz KL, Kastrati A and Byrne RA. Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016;12:e137-43.
12. Ubrich R, Kreiser K, Sinnecker D and **Schneider S**. Magnetic resonance imaging at 1.5-T in a patient with implantable leadless pacemaker. *European heart journal*. 2016;37:2441.
13. **Schneider S**, Spinner CD, Cassese S, Promny D, Hapfelmeier A, Byrne RA, Baumann M, Jager H, Steinlechner E, Laugwitz KL and Kastrati A. Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. *Aids*. 2016;30:1413-21.
14. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hoppmann P, **Schneider S**, Laugwitz KL, Schunkert H, Kastrati A, Intracoronary S and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents I. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016;11:1372-9.
15. Husser O, Kessler T, Burgdorf C, Templin C, Pellegrini C, **Schneider S**, Kasel AM, Kastrati A, Schunkert H and Hengstenberg C. Conduction Abnormalities and Pacemaker Implantations After SAPIEN 3 Vs SAPIEN XT Prosthesis Aortic Valve Implantation. *Revista espanola de cardiologia*. 2016;69:141-8.
16. Hoppmann P, Kufner S, Cassese S, Wiebe J, **Schneider S**, Piniack S, Scheler L, Bernlochner I, Joner M, Schunkert H, Laugwitz KL, Kastrati A and Byrne RA. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. *Catheter Cardiovasc Interv*. 2016;87:822-9.
17. **Schneider S**, Koch W, Hoppmann P, Ubrich R, Kemmner S, Steinlechner E, Heemann U, Laugwitz KL, Kastrati A and Baumann M. Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease. *Immunity & ageing : I & A*. 2015;12:4.
18. **Schneider S**, Hoppmann P, Koch W, Kemmner S, Schmaderer C, Renders L, Kastrati A, Laugwitz KL, Heemann U and Baumann M. Obesity-associated hypertension is ameliorated in patients with TLR4 single nucleotide polymorphism (SNP) rs4986790. *Journal of inflammation*. 2015;12:57.
19. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, **Schneider S**, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A and Sarafoff N. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After

Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. *Journal of the American College of Cardiology*. 2015;65:1619-1629.

20. Xhepa E, Byrne RA, Schulz S, Helde S, Gewalt S, Cassese S, Linhardt M, Ibrahim T, Mehilli J, Hoppe K, Grupp K, Kufner S, Bottiger C, Hoppmann P, Burgdorf C, Fusaro M, Ott I, **Schneider S**, Hengstenberg C, Schunkert H, Laugwitz KL, Kastrati A and investigators I-C. Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2014;10:198-203.
21. Schulz-Schupke S, Helde S, Gewalt S, Ibrahim T, Linhardt M, Haas K, Hoppe K, Bottiger C, Groha P, Bradaric C, Schmidt R, Bott-Flugel L, Ott I, Goedel J, Byrne RA, **Schneider S**, Burgdorf C, Morath T, Kufner S, Joner M, Cassese S, Hoppmann P, Hengstenberg C, Pache J, Fusaro M, Massberg S, Mehilli J, Schunkert H, Laugwitz KL, Kastrati A and Instrumental Sealing of Arterial Puncture Site CDvMCTI. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. *Jama*. 2014;312:1981-7.
22. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tolg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, **Schneider S**, Schunkert H, Ibrahim T, Mehilli J, Kastrati A and Bavarian Reperfusion Alternatives Evaluation I. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. *European heart journal*. 2014;35:2285-94.
23. Kasel AM, Shivaraju A, **Schneider S**, Krapf S, Oertel F, Burgdorf C, Ott I, Sumer C, Kastrati A, von Scheidt W and Thilo C. Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. *J Invasive Cardiol*. 2014;26:451-61.
24. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, **Schneider S**, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL and Kastrati A. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. *JACC Cardiovascular interventions*. 2013;6:1267-74.
25. Schulz C, Penz S, Hoffmann C, Langer H, Gillitzer A, **Schneider S**, Brandl R, Seidl S, Massberg S, Pichler B, Kremmer E, Stellos K, Schonberger T, Siess W and Gawaz M. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogession in vivo. *Basic research in cardiology*. 2008;103:356-67.
26. Massberg S, Konrad I, Schurzinger K, Lorenz M, **Schneider S**, Zohlnhoefer D, Hoppe K, Schiemann M, Kennerknecht E, Sauer S, Schulz C, Kerstan S, Rudelius M, Seidl S, Sorge F, Langer H, Peluso M, Goyal P, Vestweber D, Emambokus NR, Busch DH, Frampton J and Gawaz M. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. *The Journal of experimental medicine*. 2006;203:1221-33.
27. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, **Schneider S**, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M and Gawaz M. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2004;18:397-9.